Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (14318)	11/23/2004 10:38:38 AM
From: Gulo	Read Replies (1) \| Respond to of 52153

Miljenko or NEOL followers, Let me see if I understand this (I'm new to NEOL as well). At the AANS meeting in May, Sampson didn't look at survival, just drug distribution, right? Does this paragraph from yesterday's release mean what I think it means? The Phase I more than tripled survival (with ideal catheter placement) versus standard care? Wow. "Dr. Sampson's clinical study was based on observations to date from NeoPharm's other Phase I/II IL13-PE38QQR clinical trials indicating an increase in median survival is associated with optimal (70.3 weeks) vs. sub-optimal (41.4 weeks) catheter placement in the peritumoral setting. The median survival for this same patient population, according to publications of clinical studies with other treatments, is 20-26 weeks. " -g